<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00010387</url>
  </required_header>
  <id_info>
    <org_study_id>199/15672</org_study_id>
    <secondary_id>JHOC-J9881</secondary_id>
    <secondary_id>JHOC-99012906</secondary_id>
    <nct_id>NCT00010387</nct_id>
  </id_info>
  <brief_title>Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the response rate and 1-year event-free survival in patients with severe&#xD;
      autoimmune hematologic disease treated with high-dose cyclophosphamide.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: Patients receive high-dose cyclophosphamide IV on days 1-4 and filgrastim&#xD;
      (G-CSF) starting on day 10 and continuing until blood counts recover.&#xD;
&#xD;
      Patients are followed at 1, 3, 6, and 12 months and then annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1999</start_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>32</enrollment>
  <condition>Anemia, Hemolytic, Autoimmune</condition>
  <condition>Felty Syndrome</condition>
  <condition>Purpura, Thrombocytopenic</condition>
  <condition>Autoimmune Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
          -  Diagnosis of severe autoimmune hematologic disease Autoimmune hemolytic anemia OR&#xD;
             Immune thrombocytopenia&#xD;
&#xD;
          -  Failure of at least 2 standard treatment approaches (e.g., prednisone therapy,&#xD;
             splenectomy, intravenous immunoglobulin, or other immunosuppressants)&#xD;
&#xD;
          -  Inability to taper prednisone dose to less than 10 mg/day OR Autoimmune neutropenia&#xD;
             including the following: Felty's syndrome OR Disorders of large granular lymphocytes&#xD;
             with recurrent infections or absolute neutrophil count less than 200/mm3&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
          -  Age: Not specified&#xD;
&#xD;
          -  Performance status: Not specified&#xD;
&#xD;
          -  Hematopoietic: See Disease Characteristics&#xD;
&#xD;
          -  Hepatic: Not specified&#xD;
&#xD;
          -  Renal: Creatinine no greater than 2.5 mg/dL&#xD;
&#xD;
          -  Cardiovascular: Ejection fraction at least 40%&#xD;
&#xD;
          -  Pulmonary: FVC, FEV1, or DLCO at least 50% predicted&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Not preterminal or moribund&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert A. Brodsky</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Oncology Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>February 2, 2001</study_first_submitted>
  <study_first_submitted_qc>February 1, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2001</study_first_posted>
  <last_update_submitted>September 8, 2008</last_update_submitted>
  <last_update_submitted_qc>September 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2008</last_update_posted>
  <keyword>Felty syndrome</keyword>
  <keyword>autoimmune hemolytic anemia</keyword>
  <keyword>autoimmune neutropenia</keyword>
  <keyword>hematologic disorders</keyword>
  <keyword>immune thrombocytopenic purpura</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Felty Syndrome</mesh_term>
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Anemia, Hemolytic</mesh_term>
    <mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

